-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is reproduced from the WeChat public account of "China Biotechnology Network".
As more dangerous mutant strains of the new coronavirus spread globally, scientists and clinicians are also racing to study the protective effect of the existing new coronavirus vaccine on the mutant strain.
On April 10th, Beijing time, Science released the latest relevant report.
The preliminary results of a large study conducted by Brazilian medical staff showed that in Manaus, Brazil, more than three-quarters of new cases were caused by a highly transmissible variant strain called P.
1.
The new crown vaccine developed by Beijing Kexing Company is still about 50% effective for patients who have tested positive for nucleic acid and are symptomatic.
This means that in the real world, the protective power of the two doses of Kexing vaccine is roughly the same as the level of protection against standard or "wild-type" new coronaviruses in clinical trials.
This indicates that the mutant strain does not enhance the ability of the new coronavirus to evade the immune response induced by the vaccine.
Julio Croda, a doctor and researcher at the Oswaldo Cruz Foundation, who led the study, said: "This is very good news and supports the continued use of this vaccine in Brazil and other countries where the same variant strain exists.
" He added, vaccination The protective effect of the two-dose vaccine may be better, and pointed out that this research is ongoing.
Although the effectiveness of 50% is far lower than that of the new coronavirus vaccine by messenger RNA (mRNA) that is greater than 90% in the real world, it can still curb the spread of mutant strains in Brazil.
Vaccines with this effect in clinical trials are eligible to be approved for emergency use in many countries or places, and have also reached the threshold of the World Health Organization.
What is not clear is how effective the mRNA vaccine protects against P.
1 mutant strains.Previously, clinical trials of mRNA were carried out before the mutated virus spread or where there were few mutated viruses.
In addition, the protection rate of Kexing vaccine against serious diseases, hospitalizations and deaths is far greater than that of mild patients.
This was observed in two-dose effectiveness trials conducted in Brazil and other countries, and this is a typical feature that the new crown vaccine should have.
But Croda said the new study has not collected enough serious cases to assess its effectiveness.
The preliminary results of the study have not yet received peer review, but they were posted on the preprint server SSRN under The Lancet yesterday.
This is the first result of evaluating the effectiveness of China Kexing vaccine in areas where P.
1 mutant strains are flooded.
The source of this mutant strain named P.
1 was first discovered in Brazil in January this year and quickly spread to other countries and regions in the world.
Laboratory studies to assess whether vaccine-induced antibodies can neutralize the infectivity of the new coronavirus have raised concerns that the mutation may evade the immune protection conferred by the vaccine.
The mutated strain of the new crown is likely to have caused the resurgence of the Brazilian epidemic.
There are more than 90,000 new cases in the country, and more than 340,000 Brazilians have died.
This study involves medical data from 67,718 medical staff in Manaus, which is located in the Amazon region and is the "epicenter" of the spread of P.
1 variants.
The mutant strain now accounts for 75% of all positive cases in Manaus, where the city’s health system has collapsed due to a new wave of epidemics.
In order to evaluate the effectiveness of Kexing vaccine, the researchers focused on the study of 2,656 medical staff.
They began to undergo nucleic acid testing in January.
From the first launch of the vaccine to last week, the researchers determined that 786 had obvious symptoms of new coronary pneumonia.
People who have tested positive for the virus are divided into two groups, 393 people in each group.
Then, the researchers checked the ratio of vaccinated and unvaccinated people in the two groups.
The vaccination rate of the positive group was 18.
6%, and that of the negative group was 24.
4%. The researchers used the unvaccinated population as a reference and calculated the risk of contracting new coronary pneumonia 14 days after the first vaccination.
The results of the study found that the actual effectiveness of 49.
6% was similar to that found in a phase 3 clinical trial conducted by the Brazilian National Research Institute and the vaccine manufacturer Butantan Institute in Brazil after two doses of the vaccine were administered to patients with symptomatic new coronary pneumonia.
50.
34%.
Ricardo Palácios, an epidemiologist at the Butantan Institute, said: "This is not a coincidence.
This is an independent confirmation of the effectiveness of Kexing's vaccine under the spread of new variant strains.
" Previously, the Butantan Institute had reached an agreement with Kexing.
An agreement to produce a new crown vaccine.
However, Eric Feigl-Ding, an epidemiologist at the Federation of American Scientists, reminded that the new study did not perform genetic sequencing of people who tested positive by PCR to ensure that their infection was caused by the mutant strain P.
1.
.
He pointed out that the author's conclusion that the vaccine can prevent this mutated virus is based on the assumption that it caused most of the positive cases.
On the other hand, Feigl Ding said that testing the effectiveness of vaccines in Brazil may produce artificially low results, because they are likely to have been exposed to the virus before and develop a certain degree of immunity.
He said: "This is the natural attribute of trials in previously highly infected populations.
" This may also explain why the efficacy number (50%) of the Coxing vaccine clinical trial in Brazil is lower than that of Turkey (83.
5%) and Indonesia (65%).
%) and other countries.
Bruno Filardi, an immunopathologist at the Brazilian Cancer Institute, pointed out that because the data of the new trial comes from medical staff who are highly exposed to the mutant virus, the effectiveness of the Coxing virus may be better in the general population.
He said: "The possible effect will be higher than the preliminary research shows.
" At present, in addition to Brazil, Coxing vaccine has been authorized and used in China, Chile, Bolivia, Mexico, Turkey and Indonesia.
Croda and his colleagues will continue to analyze the effectiveness of various new crown vaccines against P.
1 and other mutant strains.
In the next two weeks, they plan to check data from the state of Sao Paulo, where more than 7 million people have been vaccinated with Coxing or AstraZeneca's new crown vaccine.
Jason Andrews, a co-author of the study and an epidemiologist at Stanford University, said that this work is a top priority.
It will be crucial to detect when the vaccine is no longer effective against the newly emerging mutant strains.
This is a question of when it will happen, not whether it will happen.
"End Reference: [1] ssrn.
com/sol3/papers.
cfm?abstract_id=3793486 Selected onlookers exercise in the past is really important! Cell publication reveals that skeletal muscle can delay brain and retina aging in a specific way.
Hot article April 2 | World Autism Inventory of hot articles on children who guard the stars together on sick days | An overview of the performance of 26 unprofitable biomedical companies in Hong Kong stocks in 2020.
Is exercise necessarily good? Cell sub-news: Excessive exercise can damage healthy people’s mitochondrial function and reduce glucose It’s no wonder that the caloric tolerance text will get fatter as you eat! Science reveals: The intestine regulates nutrient metabolism according to eating conditions.
This cell is the key "regulator".
Medical immunotherapy| Biosimilars| Vaccines| Drug resistance| Drug targets| Healthy Life| Pharmaceutical News| Drug Inventory| Pharmaceutical Technology| Fundamental Research on Drug Side Effects/Translational Medicine Leukemia| Lung Cancer| Gastric Cancer| Colorectal Cancer| Liver Cancer| Breast Cancer| Pancreatic Cancer| Cardiovascular Disease| Neurodegenerative Disease| Intestinal Microbe Medical Devices/Biotechnology In Vitro Diagnostics | Medical Devices | Bio-Nano | 3D Printing | Gene Testing | Single Cell Sequencing | Gene Editing | Assisted Reproduction | Artificial Intelligence | Precision Medicine Policy Anticancer Drugs | 4+7 Volume Procurement | Consumables | Filing System | Registrant System | Healthy China | New Edition of Essential Drug Catalog | AI Medical Devices | Telemedicine | Same-Share Equity Market/Capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | ChiNext Board | R & D Investment | Acquisition | Market & Consumption
As more dangerous mutant strains of the new coronavirus spread globally, scientists and clinicians are also racing to study the protective effect of the existing new coronavirus vaccine on the mutant strain.
On April 10th, Beijing time, Science released the latest relevant report.
The preliminary results of a large study conducted by Brazilian medical staff showed that in Manaus, Brazil, more than three-quarters of new cases were caused by a highly transmissible variant strain called P.
1.
The new crown vaccine developed by Beijing Kexing Company is still about 50% effective for patients who have tested positive for nucleic acid and are symptomatic.
This means that in the real world, the protective power of the two doses of Kexing vaccine is roughly the same as the level of protection against standard or "wild-type" new coronaviruses in clinical trials.
This indicates that the mutant strain does not enhance the ability of the new coronavirus to evade the immune response induced by the vaccine.
Julio Croda, a doctor and researcher at the Oswaldo Cruz Foundation, who led the study, said: "This is very good news and supports the continued use of this vaccine in Brazil and other countries where the same variant strain exists.
" He added, vaccination The protective effect of the two-dose vaccine may be better, and pointed out that this research is ongoing.
Although the effectiveness of 50% is far lower than that of the new coronavirus vaccine by messenger RNA (mRNA) that is greater than 90% in the real world, it can still curb the spread of mutant strains in Brazil.
Vaccines with this effect in clinical trials are eligible to be approved for emergency use in many countries or places, and have also reached the threshold of the World Health Organization.
What is not clear is how effective the mRNA vaccine protects against P.
1 mutant strains.Previously, clinical trials of mRNA were carried out before the mutated virus spread or where there were few mutated viruses.
In addition, the protection rate of Kexing vaccine against serious diseases, hospitalizations and deaths is far greater than that of mild patients.
This was observed in two-dose effectiveness trials conducted in Brazil and other countries, and this is a typical feature that the new crown vaccine should have.
But Croda said the new study has not collected enough serious cases to assess its effectiveness.
The preliminary results of the study have not yet received peer review, but they were posted on the preprint server SSRN under The Lancet yesterday.
This is the first result of evaluating the effectiveness of China Kexing vaccine in areas where P.
1 mutant strains are flooded.
The source of this mutant strain named P.
1 was first discovered in Brazil in January this year and quickly spread to other countries and regions in the world.
Laboratory studies to assess whether vaccine-induced antibodies can neutralize the infectivity of the new coronavirus have raised concerns that the mutation may evade the immune protection conferred by the vaccine.
The mutated strain of the new crown is likely to have caused the resurgence of the Brazilian epidemic.
There are more than 90,000 new cases in the country, and more than 340,000 Brazilians have died.
This study involves medical data from 67,718 medical staff in Manaus, which is located in the Amazon region and is the "epicenter" of the spread of P.
1 variants.
The mutant strain now accounts for 75% of all positive cases in Manaus, where the city’s health system has collapsed due to a new wave of epidemics.
In order to evaluate the effectiveness of Kexing vaccine, the researchers focused on the study of 2,656 medical staff.
They began to undergo nucleic acid testing in January.
From the first launch of the vaccine to last week, the researchers determined that 786 had obvious symptoms of new coronary pneumonia.
People who have tested positive for the virus are divided into two groups, 393 people in each group.
Then, the researchers checked the ratio of vaccinated and unvaccinated people in the two groups.
The vaccination rate of the positive group was 18.
6%, and that of the negative group was 24.
4%. The researchers used the unvaccinated population as a reference and calculated the risk of contracting new coronary pneumonia 14 days after the first vaccination.
The results of the study found that the actual effectiveness of 49.
6% was similar to that found in a phase 3 clinical trial conducted by the Brazilian National Research Institute and the vaccine manufacturer Butantan Institute in Brazil after two doses of the vaccine were administered to patients with symptomatic new coronary pneumonia.
50.
34%.
Ricardo Palácios, an epidemiologist at the Butantan Institute, said: "This is not a coincidence.
This is an independent confirmation of the effectiveness of Kexing's vaccine under the spread of new variant strains.
" Previously, the Butantan Institute had reached an agreement with Kexing.
An agreement to produce a new crown vaccine.
However, Eric Feigl-Ding, an epidemiologist at the Federation of American Scientists, reminded that the new study did not perform genetic sequencing of people who tested positive by PCR to ensure that their infection was caused by the mutant strain P.
1.
.
He pointed out that the author's conclusion that the vaccine can prevent this mutated virus is based on the assumption that it caused most of the positive cases.
On the other hand, Feigl Ding said that testing the effectiveness of vaccines in Brazil may produce artificially low results, because they are likely to have been exposed to the virus before and develop a certain degree of immunity.
He said: "This is the natural attribute of trials in previously highly infected populations.
" This may also explain why the efficacy number (50%) of the Coxing vaccine clinical trial in Brazil is lower than that of Turkey (83.
5%) and Indonesia (65%).
%) and other countries.
Bruno Filardi, an immunopathologist at the Brazilian Cancer Institute, pointed out that because the data of the new trial comes from medical staff who are highly exposed to the mutant virus, the effectiveness of the Coxing virus may be better in the general population.
He said: "The possible effect will be higher than the preliminary research shows.
" At present, in addition to Brazil, Coxing vaccine has been authorized and used in China, Chile, Bolivia, Mexico, Turkey and Indonesia.
Croda and his colleagues will continue to analyze the effectiveness of various new crown vaccines against P.
1 and other mutant strains.
In the next two weeks, they plan to check data from the state of Sao Paulo, where more than 7 million people have been vaccinated with Coxing or AstraZeneca's new crown vaccine.
Jason Andrews, a co-author of the study and an epidemiologist at Stanford University, said that this work is a top priority.
It will be crucial to detect when the vaccine is no longer effective against the newly emerging mutant strains.
This is a question of when it will happen, not whether it will happen.
"End Reference: [1] ssrn.
com/sol3/papers.
cfm?abstract_id=3793486 Selected onlookers exercise in the past is really important! Cell publication reveals that skeletal muscle can delay brain and retina aging in a specific way.
Hot article April 2 | World Autism Inventory of hot articles on children who guard the stars together on sick days | An overview of the performance of 26 unprofitable biomedical companies in Hong Kong stocks in 2020.
Is exercise necessarily good? Cell sub-news: Excessive exercise can damage healthy people’s mitochondrial function and reduce glucose It’s no wonder that the caloric tolerance text will get fatter as you eat! Science reveals: The intestine regulates nutrient metabolism according to eating conditions.
This cell is the key "regulator".
Medical immunotherapy| Biosimilars| Vaccines| Drug resistance| Drug targets| Healthy Life| Pharmaceutical News| Drug Inventory| Pharmaceutical Technology| Fundamental Research on Drug Side Effects/Translational Medicine Leukemia| Lung Cancer| Gastric Cancer| Colorectal Cancer| Liver Cancer| Breast Cancer| Pancreatic Cancer| Cardiovascular Disease| Neurodegenerative Disease| Intestinal Microbe Medical Devices/Biotechnology In Vitro Diagnostics | Medical Devices | Bio-Nano | 3D Printing | Gene Testing | Single Cell Sequencing | Gene Editing | Assisted Reproduction | Artificial Intelligence | Precision Medicine Policy Anticancer Drugs | 4+7 Volume Procurement | Consumables | Filing System | Registrant System | Healthy China | New Edition of Essential Drug Catalog | AI Medical Devices | Telemedicine | Same-Share Equity Market/Capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | ChiNext Board | R & D Investment | Acquisition | Market & Consumption
